C-VQKQ

FILE C-VQKQ·COMPANY·CURATED BY ETERNAL SEARCH

Prosetta

small molecules, assembly modulation, multi-protein complexes

modulatingsmall molecule

prosetta.com·San Francisco, California, United States·$31M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-VQKQ

Summary · Eternal Search editorial

Prosetta small molecules, assembly modulation, multi-protein complexes

Prosetta Biosciences is a San Francisco based biotechnology company creating innovative therapeutics for diseases. Its work focuses on identifying and advancing novel small molecules that modulate assembly of multi-protein complexes within cells. The company describes assembly-modulators as working with the body's regulatory mechanisms to restore molecular homeostasis.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite31

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Prosetta — Early mechanism · Lower middle. Derived deterministically from 9 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (3 programs at preclinical).…

Source: Deterministic

At a glance

Webprosetta.com

HQSan Francisco, California, United States

Publications

52 on file

012026Oxidized MIF is an Alzheimer's disease drug target relaying external risk factors to tau pathology.Cell reports. Medicine 022025Assessment of PAV-615: an ALS-active Assembly Modulator Small Molecule in (G4C2)149 ALS/FTD Mouse Model and Human iPSC-derived Motor Neurons (iMNs)—032025An ALS assembly modulator signature in peripheral blood mononuclear cells: implications for ALS pathophysiology, therapeutics, and diagnostics—042025Structure-Activity-Relationship Exploration and Animal Validation of Novel Assembly Modulator Small Molecule Chemical Series with Pan-Cancer Selective Cytotoxicity—052025Preclinical Evaluation of the Assembly Modulator PAV-615 in a Mouse Model of C9orf72-Associated ALS/FTD—

062025Assembly Modulation: An Emergent Drug Discovery Strategy Revealed by Viruses and Applicable Across Therapeutic Areas—

072025Oxidized MIF is an Alzheimer’s disease drug target relaying external risk factors to tau pathology—

082025Preclinical Evaluation of the Assembly Modulator PAV-615 in a Mouse Model of C9orf72-Associated ALS/FTD—

092025Assessment of PAV-615: an ALS-active Assembly Modulator Small Molecule in (G4C2)149 ALS/FTD Mouse Model and Human iPSC-derived Motor Neurons (iMNs)—102025An ALS assembly modulator signature in peripheral blood mononuclear cells: implications for ALS pathophysiology, therapeutics, and diagnostics—

112025Assembly Modulation: An Emergent Drug Discovery Strategy Revealed by Viruses and Applicable Across Therapeutic Areas—

122025Preclinical Evaluation of the Assembly Modulator PAV-615 in a Mouse Model of C9orf72-Associated ALS/FTD—

132025Assembly Modulation: An Emergent Drug Discovery Strategy Revealed by Viruses and Applicable Across Therapeutic Areas—

142025Oxidized MIF is an Alzheimer’s disease drug target relaying external risk factors to tau pathology—

152025Preclinical Evaluation of the Assembly Modulator PAV-615 in a Mouse Model of C9orf72-Associated ALS/FTD—

162025Oxidized MIF is an Alzheimer's disease drug target relaying external risk factors to tau pathology—

172025Oxidized MIF is an Alzheimer's disease drug target relaying external risk factors to tau pathology—

182025Preclinical Evaluation of the Assembly Modulator PAV-615 in a Mouse Model of C9orf72-Associated ALS/FTD—

192025Assembly Modulation: An Emergent Drug Discovery Strategy Revealed by Viruses and Applicable Across Therapeutic Areas—

202025An ALS assembly modulator signature in peripheral blood mononuclear cells: implications for ALS pathophysiology, therapeutics, and diagnostics.Clinical proteomics

212025Oxidized MIF is an Alzheimer’s disease drug target relaying external risk factors to tau pathology—

222025Preclinical Evaluation of the Assembly Modulator PAV-615 in a Mouse Model of C9orf72-Associated ALS/FTD—

232025Assembly Modulation: An Emergent Drug Discovery Strategy Revealed by Viruses and Applicable Across Therapeutic Areas—

242025Oxidized MIF is an Alzheimer’s disease drug target relaying external risk factors to tau pathology—252025Preclinical Evaluation of the Assembly Modulator PAV-615 in a Mouse Model of C9orf72-Associated ALS/FTD.Cells 262024A pan-respiratory antiviral chemotype targeting a transient host multi-protein complex.Open biology 272024A Pan-Respiratory Antiviral Chemotype Targeting a Transient Host Multi-Protein Complex—282024A viral assembly inhibitor blocks SARS-CoV-2 replication in airway epithelial cells—292024Small molecule protein assembly modulators with pan-cancer therapeutic efficacy—302024A viral assembly inhibitor blocks SARS-CoV-2 replication in airway epithelial cells.Communications biology 312024Protein Assembly Modulation: A New Approach to Amyotrophic Lateral Sclerosis (ALS) Therapeutics—322024Small molecule protein assembly modulators with pan-cancer therapeutic efficacy.Open biology 332024Protein Assembly Modulation: A New Approach to Amyotrophic Lateral Sclerosis (ALS) Therapeutics.Journal of experimental neurology 342023A Pan-Respiratory Antiviral Chemotype Targeting a Host Multi-Protein Complex.bioRxiv : the preprint server for biology 352023A Novel Viral Assembly Inhibitor Blocks SARS-CoV-2 Replication in Airway Epithelial Cells.Research square 362021Addressing Antiretroviral Drug Resistance with Host-Targeting Drugs-First Steps towards Developing a Host-Targeting HIV-1 Assembly Inhibitor.Viruses 372021Identification of an Antiretroviral Small Molecule That Appears To Be a Host-Targeting Inhibitor of HIV-1 Assembly.Journal of virology 382021New methylene blue derivatives suggest novel anti-orthopoxviral strategies.Antiviral research 392021Viruses as 'Truffle Hounds': Molecular Tools for Untangling Brain Cellular Pathology.Trends in neurosciences 402021Multifunctionality of Prostatic Acid Phosphatase in Prostate  Cancer Pathogenesis.Bioscience reports 412021Determination of the membrane topology of PORCN, an O-acyl transferase that modifies Wnt signalling proteins.Open biology 422021Multifunctionality of prostatic acid phosphatase in prostate cancer pathogenesis.Bioscience reports 432020Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation.Proceedings of the National Academy of Sciences of the United States of America 442020MksB, an alternate condensin from Mycobacterium smegmatis is involved in DNA binding and condensation.Biochimie 452018Formation of RNA Granule-Derived Capsid Assembly Intermediates Appears To Be Conserved between Human Immunodeficiency Virus Type 1 and the Nonprimate Lentivirus Feline Immunodeficiency Virus.Journal of virology 462016Biochemical and biophysical characterization of cell-free synthesized Rift Valley fever virus nucleoprotein capsids enables in vitro screening to identify novel antivirals.Biology direct 472016Divergent effects of Porcupine and Wntless on WNT1 trafficking, secretion, and signaling.Experimental cell research 482015Viral capsid assembly as a model for protein aggregation diseases: Active processes catalyzed by cellular assembly machines comprising novel drug targets.Virus research 492013Host-rabies virus protein-protein interactions as druggable antiviral targets—502013Host-rabies virus protein-protein interactions as druggable antiviral targets.Proceedings of the National Academy of Sciences of the United States of America 512013Capsid assembly as a point of intervention for novel anti-viral therapeutics.Current pharmaceutical biotechnology 522005Recent Insights into Biological Regulation from Cell-Free Protein-Synthesizing Systems—

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Prosetta

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.